Aflibercept treatment for macular edema following branch retinal vein occlusion and thinning fovea

Poster Details

First Author: D.Muramatsu JAPAN

Co Author(s):    Y. Wakabayashi   M. Miura   S. Kawakami   K. Yamamoto   K. Umazume   H. Goto              

Abstract Details


To assess the efficacy of aflibercept treatment in Japanese patients with macular edema following branch retinal vein occlusion (BVO) and the frequency of thinning fovea.


Tokyo Medical University Hospital Tokyo Medical University, Ibaraki Medical centre


Retrospective case series. Nineteen cases of BVO who received intravitreal injection of aflibercpt (IVA) at Tokyo Medical University (TMU) hospital and TMU-Ibaraki Medical centre between June 2015 and December were enrolled. Ten eyes were anti-VEGF treatment naïve cases and 9 eyes were switched cases from ranibizumab. Treatment regimen was as-needed therapy. The main outcomes were BCVA (LogMAR) and CRT evaluated at 1, 3, 6 months and final visit after primary IVA and the percentage of thinning fovea.


The percentage of eyes that given single IVA or more than 2 IVA was 11% and 89%. The average number of IVA was 2.8±1.0 times. Baseline BCVA was 0.36 ±0.32. At 1, 3, 6 months and at the final visit, BCVA improved to 0.25±0.29, 0.20±0.26, 0.21±0.32 and 0.18±0.31 respectively. Three months and final VA were improved significantly. Baseline CRT was 556 ±191μm. CRT decreased significantly to 295μm ±86, 325 ±119, 323 ±93 and 286 ±108, respectively (p<0.01; t-test) However, thinning fovea cases with CRT less than 220 um was observed in 35%.


IVA improved macular structure for patients with BVO for 6 months. Further research is needed for treatment regimen, especially for patients with thin CRT.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email:

Privacy policyHotel Terms and Conditions Cancellation policy